Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 428

1.

Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.

Wong IC, Asherson P, Bilbow A, Clifford S, Coghill D, DeSoysa R, Hollis C, McCarthy S, Murray M, Planner C, Potts L, Sayal K, Taylor E.

Health Technol Assess. 2009 Oct;13(50):iii-iv, ix-xi, 1-120. doi: 10.3310/hta13490.

2.

Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults.

McCarthy S, Asherson P, Coghill D, Hollis C, Murray M, Potts L, Sayal K, de Soysa R, Taylor E, Williams T, Wong IC.

Br J Psychiatry. 2009 Mar;194(3):273-7. doi: 10.1192/bjp.bp.107.045245.

3.

The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care.

McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC.

BMC Pediatr. 2012 Jun 19;12:78. doi: 10.1186/1471-2431-12-78.

4.

Management of adult attention deficit hyperactivity disorder in UK primary care: a survey of general practitioners.

McCarthy S, Wilton L, Murray M, Hodgkins P, Asherson P, Wong IC.

Health Qual Life Outcomes. 2013 Feb 22;11:22. doi: 10.1186/1477-7525-11-22.

5.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
6.

[Prescribing of stimulants for ADHD in Nordland County].

Asheim H, Nilsen KB, Johansen K, Furu K.

Tidsskr Nor Laegeforen. 2007 Sep 20;127(18):2360-2. Norwegian.

7.

Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.

Sasané R, Hodgkins P, Meijer W.

Curr Med Res Opin. 2010 Nov;26(11):2565-74. doi: 10.1185/03007995.2010.518131. Epub 2010 Sep 23.

PMID:
20863165
8.

Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.

Fredriksen M, Dahl AA, Martinsen EW, Klungsøyr O, Haavik J, Peleikis DE.

Eur Neuropsychopharmacol. 2014 Dec;24(12):1873-84. doi: 10.1016/j.euroneuro.2014.09.013. Epub 2014 Oct 18.

PMID:
25453480
9.

Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.

Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, Saidi A.

Ann Pharmacother. 2008 Jan;42(1):24-31. Epub 2007 Nov 27.

PMID:
18042808
10.
11.

Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.

Christensen L, Sasané R, Hodgkins P, Harley C, Tetali S.

Curr Med Res Opin. 2010 Apr;26(4):977-89. doi: 10.1185/03007991003673617.

PMID:
20178404
12.

The use of medication against attention deficit/hyperactivity disorder in Denmark: a drug use study from a patient perspective.

Pottegård A, Bjerregaard BK, Glintborg D, Kortegaard LS, Hallas J, Moreno SI.

Eur J Clin Pharmacol. 2013 Mar;69(3):589-98. doi: 10.1007/s00228-012-1344-0. Epub 2012 Jul 19.

PMID:
22811260
13.

Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder.

Bédard AC, Stein MA, Halperin JM, Krone B, Rajwan E, Newcorn JH.

J Child Psychol Psychiatry. 2015 Jan;56(1):40-8. doi: 10.1111/jcpp.12272. Epub 2014 Jun 19.

14.

Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence.

McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC.

BMC Psychiatry. 2012 Dec 5;12:219. doi: 10.1186/1471-244X-12-219.

15.

A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.

Soutullo C, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Bloomfield R, Squires LA, Coghill DR.

CNS Drugs. 2013 Sep;27(9):743-51. doi: 10.1007/s40263-013-0086-6.

16.

Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands.

Hodgkins P, Sasané R, Meijer WM.

Clin Ther. 2011 Feb;33(2):188-203. doi: 10.1016/j.clinthera.2011.03.001.

PMID:
21497704
17.

A nationwide study of attention-deficit/hyperactivity disorder drug use among adults in Iceland 2003-2012.

Geirs DP, Pottegård A, Halldórsson M, Zoëga H.

Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):417-22. doi: 10.1111/bcpt.12243. Epub 2014 May 6.

18.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
19.

Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.

Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann-Mayer C; 31001074-ATT2001 Study Investigators.

CNS Drugs. 2012 May 1;26(5):421-34. doi: 10.2165/11631990-000000000-00000.

PMID:
22519922
20.

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R.

Health Technol Assess. 2006 Jul;10(23):iii-iv, xiii-146. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk